+

WO2009036768A3 - Diagnostic de la prise de poids potentielle chez un sujet - Google Patents

Diagnostic de la prise de poids potentielle chez un sujet Download PDF

Info

Publication number
WO2009036768A3
WO2009036768A3 PCT/DK2008/050227 DK2008050227W WO2009036768A3 WO 2009036768 A3 WO2009036768 A3 WO 2009036768A3 DK 2008050227 W DK2008050227 W DK 2008050227W WO 2009036768 A3 WO2009036768 A3 WO 2009036768A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
present
invention further
further relates
weight gain
Prior art date
Application number
PCT/DK2008/050227
Other languages
English (en)
Other versions
WO2009036768A2 (fr
Inventor
Benny Bang-Andersen
John Nicholas Pearson
Original Assignee
Lundbeck & Co As H
Benny Bang-Andersen
John Nicholas Pearson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H, Benny Bang-Andersen, John Nicholas Pearson filed Critical Lundbeck & Co As H
Publication of WO2009036768A2 publication Critical patent/WO2009036768A2/fr
Publication of WO2009036768A3 publication Critical patent/WO2009036768A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de diagnostic ou de pronostic d'un syndrome métabolique potentiel chez un sujet. La présente invention concerne en outre un procédé de diagnostic ou de pronostic d'un syndrome métabolique potentiel chez un sujet pouvant être induit par des médicaments. La présente invention porte par ailleurs sur l'utilisation d'un agent dans la fabrication d'un médicament destiné à traiter un trouble ou une maladie chez un sujet. La présente invention porte également sur un agent à utiliser dans un procédé destiné à traiter un trouble ou une maladie chez un sujet. En outre, l'invention concerne un procédé de traitement d'un trouble ou d'une maladie chez un sujet, comprenant l'administration d'une quantité thérapeutiquement efficace d'un agent à un sujet. Enfin, la présente invention concerne un procédé d'identification d'un composé anti-psychotique.
PCT/DK2008/050227 2007-09-19 2008-09-18 Diagnostic de la prise de poids potentielle chez un sujet WO2009036768A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97346607P 2007-09-19 2007-09-19
DKPA200701353 2007-09-19
DKPA200701353 2007-09-19
US60/973,466 2007-09-19

Publications (2)

Publication Number Publication Date
WO2009036768A2 WO2009036768A2 (fr) 2009-03-26
WO2009036768A3 true WO2009036768A3 (fr) 2009-08-20

Family

ID=40291125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050227 WO2009036768A2 (fr) 2007-09-19 2008-09-18 Diagnostic de la prise de poids potentielle chez un sujet

Country Status (1)

Country Link
WO (1) WO2009036768A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
JP2018506720A (ja) * 2015-02-13 2018-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｃｃｐおよび抗ｐｉｋ３ｃｄを測定することによる関節リウマの査定方法
CN115616113B (zh) * 2022-10-18 2024-08-06 江苏慈星药业有限公司 一种利用hplc测定氯氮平原料药中杂质含量的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104239A1 (fr) * 2002-06-05 2003-12-18 Ivax Corporation Compose pour le traitement de troubles du systeme nerveux central (snc)
WO2006114606A1 (fr) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Derives de thiazole fusionne en tant qu'inhibiteurs de la kinase
WO2007050318A2 (fr) * 2005-10-24 2007-05-03 Duke University Approches lipidomiques de troubles du systeme nerveux central
US20070154576A1 (en) * 2005-12-09 2007-07-05 Tripp Matthew L Protein kinase modulation by hops and Acacia products
WO2007129113A2 (fr) * 2006-05-02 2007-11-15 University Of Southampton Prédiction de phénotypes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104239A1 (fr) * 2002-06-05 2003-12-18 Ivax Corporation Compose pour le traitement de troubles du systeme nerveux central (snc)
WO2006114606A1 (fr) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Derives de thiazole fusionne en tant qu'inhibiteurs de la kinase
WO2007050318A2 (fr) * 2005-10-24 2007-05-03 Duke University Approches lipidomiques de troubles du systeme nerveux central
US20070154576A1 (en) * 2005-12-09 2007-07-05 Tripp Matthew L Protein kinase modulation by hops and Acacia products
WO2007129113A2 (fr) * 2006-05-02 2007-11-15 University Of Southampton Prédiction de phénotypes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AUBIN D ET AL: "Phosphoinositide 3-kinase is required for human adipocyte differentiation in culture", INTERNATIONAL JOURNAL OF OBESITY, vol. 29, no. 8, August 2005 (2005-08-01), pages 1006 - 1009, XP002513344, ISSN: 0307-0565 *
CHAUSSADE CLAIRE ET AL: "Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling", BIOCHEMICAL JOURNAL, vol. 404, no. Part 3, June 2007 (2007-06-01), pages 449 - 458, XP002513345, ISSN: 0264-6021(print) 1470-8728(ele *
ENGL J ET AL: "Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells", December 2005, MOLECULAR PSYCHIATRY, VOL. 10, NR. 12, PAGE(S) 1089-1096, ISSN: 1359-4184, XP002534587 *
GRAY ALEXANDER ET AL: "Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts.", 15 February 2003, ANALYTICAL BIOCHEMISTRY, VOL. 313, NR. 2, PAGE(S) 234-245, ISSN: 0003-2697, XP002513347 *
HENRY CHANTAL ET AL: "Olanzapine-induced mania in bipolar disorders", JOURNAL OF PSYCHIATRY AND NEUROSCIENCE, vol. 27, no. 3, May 2002 (2002-05-01), pages 200 - 201, XP002534585, ISSN: 1180-4882 *
LU XIAO-HONG ET AL: "Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38", BRAIN RESEARCH, vol. 1011, no. 1, 11 June 2004 (2004-06-11), pages 58 - 68, XP002534586, ISSN: 0006-8993 *
OKKENHAUG KLAUS ET AL: "Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice", 9 August 2002, SCIENCE (WASHINGTON D C), VOL. 297, NR. 5583, PAGE(S) 1031-1034, ISSN: 0036-8075, XP002513346 *
ROTHSCHILD A J ET AL: "OLANZAPINE RESPONSE IN PSYCHOTIC DEPRESSION", JOURNAL OF CLINICAL PSYCHIATRY,, vol. 60, no. 2, 1 February 1999 (1999-02-01), pages 116 - 118, XP008016700, ISSN: 0160-6689 *

Also Published As

Publication number Publication date
WO2009036768A2 (fr) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2012021629A3 (fr) Nouveaux agonistes du récepteur dopaminergique d3 pour traiter la dyskinésie dans la maladie de parkinson
WO2008124085A3 (fr) Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
EP2512479A4 (fr) Méthodes et compositions destinées au traitement de maladies vasculaires périphériques
WO2010029089A3 (fr) Polythérapie pour le traitement du diabète et des états pathologiques apparentés
MX2012014934A (es) Antagonistas de ciclohexilacetindinilo del receptor de la citocina quimioatrayente 2.
MX2011010964A (es) Antagonistas del receptor 2 de citocina quimioatrayente de 4- azetidinil-1-fenil-ciclohexano.
WO2007133731A3 (fr) Composés de ligand de créatine et procédés d'utilisation correspondants
WO2007076295A3 (fr) Nanoagrégats pour l'administration de substances thérapeutiques
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
BR112012012903A2 (pt) compostos de espiropiperidina
WO2007092936A3 (fr) Procédé pour traiter des lésions gastriques
WO2010144336A3 (fr) Procédés de traitement de maladie rénale chronique
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
WO2007138466A3 (fr) Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
WO2009002808A3 (fr) Composés de quinazolinone et leurs méthodes d'utilisation
WO2012054535A3 (fr) Composés, compositions et méthodes utiles pour la mobilisation du cholestérol
WO2013049725A3 (fr) Procédés d'utilisation de l'activation du récepteur a1 de l'adénosine pour le traitement de la dépression
MX2011010919A (es) Antagonistas del receptor 2 de citocina quimioatrayente de 4-azetidinil-1-heteroaril-ciclohexano.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08801403

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08801403

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载